References in periodicals archive ?
Researchers claim that Aromasin reduces the risk of invasive breast cancer by 65% compared to a placebo.
A 2004 study, co-ordinated by Cancer Research UK, found that patients who switched from tamoxifen to Aromasin halfway through treatment reduced the risk of the disease returning by a third.
39) Femara only mildly inhibits 3A4; Arimidex moderately inhibits 3A4; Aromasin is metabolized by 3A4 and has the greatest risk of interactions with other 3A4-metabolised drugs.
The latest study conducted by Canada's NCIC Clinical Trials Group revealed that a drug called Exemestane, sold under the brand name Aromasin, now used to prevent recurrences of breast cancer can also prevent it from occurring in the first place.
The use of Aromasin in this setting is supported by the landmark IES trial.
New Data On Pfizer's Aromasin and Ellence to Be Presented at San Antonio
Researchers found Aromasin could reduce the risk of post-menopausal women dying by 17 per cent compared with standard therapy - saving up to 1,000 lives per year.
The Scottish Medicines Consortium have given the green light to Aromasin, one of a new generation of drugs.
Femara, Breast cancer, Letrozole, Sales forecast, Aromatase Inhibitor, Phase III, Phase 3, Pipeline, Competitors to Aromasin, Arimidex, Xeloda, Faslodex, Novartis, Hormonal drug, Branded, Oral drug
Aromasin lost patent protection in the United States in April, and will lose it in Europe in July, according to company spokesman Christopher Loder.
New York) said new research shows that switching breast cancer patients onto its Aromasin half way through a five-year course of tamoxifen improves their chance of staying cancer-free for at least the next six years.